MARKET

KTRA

KTRA

Kintara Therapeutics Inc
NASDAQ
0.1373
+0.0046
+3.47%
Pre Market: 0.1370 -0.0003 -0.22% 04:32 04/25 EDT
OPEN
0.1306
PREV CLOSE
0.1327
HIGH
0.1442
LOW
0.1298
VOLUME
90
TURNOVER
0
52 WEEK HIGH
5.98
52 WEEK LOW
0.0810
MARKET CAP
5.36M
P/E (TTM)
-0.0230
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Tuesday's Intraday Session
VolitionRX (AMEX:VNRX) shares rose 33.6% to $0.8 during Tuesday's regular session. Palisade Bio (NASDAQ:PALI) stock increased by 29.81% during the session. Kintara Therapeutics and NKGen Biotech were among the losers.
Benzinga · 1d ago
Weekly Report: what happened at KTRA last week (0415-0419)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Mobile-health Network (NASDAQ:MNDR) shares increased by 34.7% to $27.44 during Friday's regular session. NKGen Biotech stock increased by 19.76% and Adlai Nortye stock moved upwards by 16.33%. Other losers include SeaStar Medical Holding and iSpecimen.
Benzinga · 5d ago
Weekly Report: what happened at KTRA last week (0408-0412)?
Weekly Report · 04/15 10:22
Weekly Report: what happened at KTRA last week (0401-0405)?
Weekly Report · 04/08 10:25
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Byrna Technologies shares jumped 7.1% to $14.74 on Friday. The company reported better-than-expected first-quarter revenue and announced a CFO transition. MediaCo Holding Inc. Shares jumped 141.7% in today's mid-day session.
Benzinga · 04/05 17:06
12 Health Care Stocks Moving In Friday's Intraday Session
Candel Therapeutics (NASDAQ:CADL) stock increased by 27.6% to $8.17 during Friday's regular session. The company's market cap stands at $239.6 million. Galectin Therapeutic shares increased by 20.66% and Ocugen stock moved upwards by 17.88%. Candel Therapeutical is one of the top gainers in the sector.
Benzinga · 04/05 16:31
KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA
Former Attorney General of Louisiana Charles C. Foti, Jr. And the law firm of Kahn Swick & Foti are investigating the proposed merger of Kintara Therapeutics, Inc. And TuHura Biosciences. KSF is seeking to determine whether the merger is fair to shareholders.
Barchart · 04/05 12:31
More
About KTRA
Kintara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of new cancer therapies. It is focused on the development of novel cancer therapies for patients with unmet medical needs. Its two candidates include VAL-083 and REM-001. VAL-083 is a novel, validated, deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC), and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC), basal cell carcinoma nevus syndrome (BCCNS), and access graft failure in hemodialysis patients. VAL-083 is being evaluated in all three GBM patient subtypes in the GBM AGILE Study: newly diagnosed methylated MGMT; newly diagnosed unmethylated MGMT, and recurrent.

Webull offers Kintara Therapeutics Inc stock information, including NASDAQ: KTRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KTRA stock methods without spending real money on the virtual paper trading platform.